NEW YORK (Reuters) - The Takeda Pharmaceutical Co-led group that is developing a blood plasma treatment for COVID-19 has started manufacturing while the late-stage trial to determine whether it works is ongoing, Takeda <4502.T> Chief Executive Christophe Weber said on Monday.
from Latest News https://ift.tt/3lAreeE
Tuesday, 13 October 2020
Takeda group begins manufacturing Covid plasma treatment ahead of approval
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment